Radioactive main group and rare earth metals for imaging and therapy
Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …
medicine with great success for several decades. The majority of current clinical use …
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
L Emmett, K Willowson, J Violet, J Shin… - Journal of medical …, 2017 - Wiley Online Library
Prostate‐specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer
cells that is revolutionising the way we image and treat men with prostate cancer. New small …
cells that is revolutionising the way we image and treat men with prostate cancer. New small …
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor-and PSMA-targeting ligands
K Sjögreen Gleisner, N Chouin, PM Gabina… - European journal of …, 2022 - Springer
The purpose of the EANM Dosimetry Committee is to provide recommendations and
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, R Baum… - European journal of …, 2019 - Springer
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can
be identified by PSMA-ligand imaging, which has already become clinically accepted in …
be identified by PSMA-ligand imaging, which has already become clinically accepted in …
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
JJ Zaknun, L Bodei, J Mueller-Brand, ME Pavel… - European journal of …, 2013 - Springer
Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy
involving the systemic administration of a radiolabelled peptide designed to target with high …
involving the systemic administration of a radiolabelled peptide designed to target with high …
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
L Bodei, M Kidd, G Paganelli, CM Grana… - European journal of …, 2015 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) with 90 Y and 177 Lu provides
objective responses in neuroendocrine tumours, and is well tolerated with moderate toxicity …
objective responses in neuroendocrine tumours, and is well tolerated with moderate toxicity …
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model
Y Liu, T Watabe, K Kaneda-Nakashima… - European Journal of …, 2022 - Springer
Purpose Fibroblast activation protein (FAP), which has high expression in cancer-associated
fibroblasts of epithelial cancers, can be used as a theranostic target. Our previous study …
fibroblasts of epithelial cancers, can be used as a theranostic target. Our previous study …
213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
C Kratochwil, FL Giesel, F Bruchertseifer… - European journal of …, 2014 - Springer
Purpose Radiopeptide therapy using a somatostatin analogue labelled with a beta emitter
such as 90 Y/177 Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer …
such as 90 Y/177 Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer …
MIRD pamphlet no. 26: joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy
The accuracy of absorbed dose calculations in personalized internal radionuclide therapy is
directly related to the accuracy of the activity (or activity concentration) estimates obtained at …
directly related to the accuracy of the activity (or activity concentration) estimates obtained at …
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and …
U Garske-Román, M Sandström, K Fröss Baron… - European journal of …, 2018 - Springer
Purpose Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has
yielded promising results. This prospective study investigated the feasibility of dosimetry of …
yielded promising results. This prospective study investigated the feasibility of dosimetry of …